cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd3+-DOTA chelates for α(v)β3 integrin-targeted tumor imaging (MRI).
cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd3+-DOTA chelates for α(v)β3 integrin-targeted tumor imaging (MRI).
复制标题
DOI:
10.1021/ic302340c
复制
发表时间:
2013-02-18
影响因子:
4.6
通讯作者:
Hawthorne MF
中科院分区:
文献类型:
--
作者:
Goswami LN;Ma L;Cai Q;Sarma SJ;Jalisatgi SS;Hawthorne MF
A vertex-differentiated icosahedral closo-B122− core was utilized to construct a αvβ3 integrin receptor-targeted (via cRGD peptide) high payload MRI contrast agent (CA-12) carrying 11 copies of Gd3+-DOTA chelates attached to the closo-B122− surface via suitable linkers. The resulting polyfunctional MRI contrast agent possessed a higher relaxivity value per-Gd compared to Omniscan, a small molecular contrast agent commonly used in clinical settings. The αvβ3 integrin receptor specificity of CA-12 was confirmed via in vitro cellular binding experiments and in vivo MRI of mice bearing human PC-3 prostate cancer xenografts. Integrin αvβ3-positive MDA-MB-231 cells exhibited 300% higher uptake of CA-12 than αvβ3-negative T47D cells. Serial T1-weighted MRI showed superior contrast enhancement of tumors by CA-12 compared to both a non-targeted 12-fold Gd3+-DOTA closomer control (CA-7) and Omniscan. Contrast enhancement by CA-12 persisted for 4 h post-injection, and subsequent enhancement of kidney tissue indicated a renal elimination route similar to Omniscan. No toxic effects of CA-12 were apparent in any mice for up to 24 h post-injection. Post-mortem ICP-OES analysis at 24 hours detected no residual Gd in any of the tissue samples analyzed.
登录
查看更多内容
影响因子:
8.8
作者:
通讯作者:
--
影响因子:
15
作者:
Floyd WC 3rd;Klemm PJ;Smiles DE;Kohlgruber AC;Pierre VC;Mynar JL;Fréchet JM;Raymond KN
通讯作者:
Raymond KN
影响因子:
3.3
作者:
Li, Wei;Su, Bo;Zhou, Caicun
通讯作者:
Zhou, Caicun
影响因子:
12.4
作者:
Chen K;Chen X
通讯作者:
Chen X
影响因子:
4.6
作者:
Goswami LN;Ma L;Chakravarty S;Cai Q;Jalisatgi SS;Hawthorne MF
通讯作者:
Hawthorne MF